Literature DB >> 11071649

Constitutive activation of STAT3 is associated with the acquisition of an interleukin 6-independent phenotype by murine plasmacytomas and hybridomas.

R Rawat1, G J Rainey, C D Thompson, M R Frazier-Jessen, R T Brown, R P Nordan.   

Abstract

Interleukin 6 (IL-6), the major growth factor for myeloma cells, signals through the activation of signal transducers and activators of transcription (STAT) proteins. An important step in the malignant progression of murine plasmacytomas is the transition from dependence on IL-6 to a state of IL-6 independence. To elucidate the mechanism whereby IL-6 independence occurs, intracellular signaling events elicited by IL-6 in both IL-6-dependent and -independent plasmacytomas and hybridomas were compared. It was found that STAT3, a key molecule involved in IL-6 signaling, was constitutively activated and phosphorylated in IL-6-independent cell lines compared to the IL-6-dependent cells. Further comparison of upstream signaling pathways revealed that JAK-1 was constitutively present in anti-phosphotyrosine immunoprecipitates of IL-6-independent cells; gp130 was constitutively phosphorylated in a subset of IL-6-independent plasmacytomas, whereas other IL-6-independent lines showed no detectable gp130 phosphorylation in the absence of exogenous IL-6. Secretion of a factor capable of supporting the growth of IL-6-dependent cells was observed in one of the IL-6-independent plasmacytomas, but not in others, making an autocrine mechanism an unlikely explanation for IL-6 independence. These findings provide evidence that the constitutive activation of STAT3, either in the absence of detectable receptor-proximal events or associated with the concomitant activation of gp130, can contribute to the process of IL-6 independence.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11071649

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  Forced dimerization of gp130 leads to constitutive STAT3 activation, cytokine-independent growth, and blockade of differentiation of embryonic stem cells.

Authors:  Christiane Stuhlmann-Laeisz; Sigrid Lang; Athena Chalaris; Paliga Krzysztof; Sudarman Enge; Jutta Eichler; Ursula Klingmüller; Michael Samuel; Matthias Ernst; Stefan Rose-John; Jürgen Scheller
Journal:  Mol Biol Cell       Date:  2006-04-19       Impact factor: 4.138

2.  IL-6 transgenic mouse model for extraosseous plasmacytoma.

Authors:  Alexander L Kovalchuk; Joong Su Kim; Sung Sup Park; Allen E Coleman; Jerrold M Ward; Herbert C Morse; Tadamitsu Kishimoto; Michael Potter; Siegfried Janz
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

3.  Constitutive NF-kappaB activation confers interleukin 6 (IL6) independence and resistance to dexamethasone and Janus kinase inhibitor INCB018424 in murine plasmacytoma cells.

Authors:  Yanqiang Yang; Jason S Groshong; Hittu Matta; Ramakrishnan Gopalakrishnan; Han Yi; Preet M Chaudhary
Journal:  J Biol Chem       Date:  2011-06-24       Impact factor: 5.157

4.  Kaposi's Sarcoma-Associated Herpesvirus Latency Locus Compensates for Interleukin-6 in Initial B Cell Activation.

Authors:  Sang-Hoon Sin; Sun Ah Kang; Yongbaek Kim; Anthony Eason; Kelly Tan; Hyowon An; Dirk P Dittmer
Journal:  J Virol       Date:  2015-12-09       Impact factor: 5.103

5.  The protein tyrosine phosphatase CD45 is required for interleukin 6 signaling in U266 myeloma cells.

Authors:  Qun Zhou; Yuan Yao; Solveig G Ericson
Journal:  Int J Hematol       Date:  2004-01       Impact factor: 2.490

6.  Forced homo- and heterodimerization of all gp130-type receptor complexes leads to constitutive ligand-independent signaling and cytokine-independent growth.

Authors:  Jan Suthaus; Anna Tillmann; Inken Lorenzen; Elena Bulanova; Stefan Rose-John; Jürgen Scheller
Journal:  Mol Biol Cell       Date:  2010-06-16       Impact factor: 4.138

7.  Phospho-flow detection of constitutive and cytokine-induced pSTAT3/5, pAKT and pERK expression highlights novel prognostic biomarkers for patients with multiple myeloma.

Authors:  R Brown; S Yang; C Weatherburn; J Gibson; P J Ho; H Suen; D Hart; D Joshua
Journal:  Leukemia       Date:  2014-07-03       Impact factor: 11.528

8.  RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma.

Authors:  Siqing Wang; Guido Tricot; Lei Shi; Wei Xiong; Zhaoyang Zeng; Hongwei Xu; Maurizio Zangari; Bart Barlogie; John D Shaughnessy; Fenghuang Zhan
Journal:  Blood       Date:  2009-05-20       Impact factor: 22.113

9.  Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo.

Authors:  Renate Burger; Steven Le Gouill; Yu-Tzu Tai; Reshma Shringarpure; Pierfrancesco Tassone; Paola Neri; Klaus Podar; Laurence Catley; Teru Hideshima; Dharminder Chauhan; Eian Caulder; Claire L Neilan; Kris Vaddi; Jun Li; Martin Gramatzki; Jordan S Fridman; Kenneth C Anderson
Journal:  Mol Cancer Ther       Date:  2009-01       Impact factor: 6.261

10.  INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.

Authors:  Jun Li; Margaret Favata; Jennifer A Kelley; Eian Caulder; Beth Thomas; Xiaoming Wen; Richard B Sparks; Ari Arvanitis; James D Rogers; Andrew P Combs; Kris Vaddi; Kimberly A Solomon; Peggy A Scherle; Robert Newton; Jordan S Fridman
Journal:  Neoplasia       Date:  2010-01       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.